Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 27, 2007

Wyeth Sells 10 Drugs for Almost $76.5M

  • Meda purchased 10 European on-market drugs from Wyeth for SEK 525 million, or approximately $76.49 million.

    Meda expects the products to add about SEK 160-170 million, or between $23 million and $25.41 million, in sales into its operation for the rest of 2007. It reports that the acquisition enhances its position in two of its most important markets, Italy and France. These countries account for about 60% of the acquired products' sales, according to the company.

    Meda states that the biggest product acquired through this deal is Seresta®, an anti-anxiety agent used for sleep disorders and various substance-withdrawal syndromes.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »